Pretomanid

Edina Avdic, Pharm.D.
Pediatric Dosing Author: Lisa Hutchins, Pharm.D.
Pretomanid is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of adults with pulmonary extensively drug-resistant (XDR) TB and treatment-intolerant or nonresponsive multidrug-resistant (MDR) TB in a combination regimen with bedaquiline and linezolid.
    • Limitations of Use: Pretomanid is not indicated for patients with drug-sensitive TB, latent TB, extra-pulmonary infection due to M. tuberculosis, MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy
    • Safety and effectiveness have not been established in combination with drugs other than bedaquiline and linezolid.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Treatment of adults with pulmonary extensively drug-resistant (XDR) TB and treatment-intolerant or nonresponsive multidrug-resistant (MDR) TB in a combination regimen with bedaquiline and linezolid.
    • Limitations of Use: Pretomanid is not indicated for patients with drug-sensitive TB, latent TB, extra-pulmonary infection due to M. tuberculosis, MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy
    • Safety and effectiveness have not been established in combination with drugs other than bedaquiline and linezolid.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: January 12, 2020